Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2014-09-30
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this RCT, 60 patients aged 18-65 with early psychosis less than 5 years' duration and mild depressive mood or anxiety will be invited to join this single blind randomized controlled trial. After baseline assessments, eligible participants will be, using third party simple randomization, randomly assigned to either the 7-week Mindfulness-based Intervention (MBI), or the psychoeducation group as control.
The primary outcome is depressive mood and anxiety levels at post-intervention and 3 months. The secondary outcomes include life functioning, quality of life, other general clinical symptoms and mindfulness ability. Qualitative interviews will help evaluate and measure the feasibility of the intervention. Data will be analyzed according to the intention-to-treat principle.
This randomized trial offers an insight into mindfulness-based intervention and its effectiveness on psychosis concomitants. It provides the foundation for future evaluation and implementation of an effective and cost-efficient treatment option.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mindfulness Intervention and Relapse in Psychosis
NCT04060498
Mindfulness-Based Family Psychoeducation Intervention for Early Psychosis
NCT03688009
Mindfulness, Group Therapy and Psychosis; Training Decreases Anxiety and Depression
NCT04711460
Motivational Intervention for Physical Activity in Psychosis
NCT02648321
The Effects and Mechanisms of Mindfulness Intervention for Emotional Distress
NCT05606224
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Mindfulness is the awareness that emerges from paying attention to the present moment without judgment. It is a skill that can be achieved through meditation practices, and has been shown to improve general well-being. Mindfulness-based intervention (MBI) has been referred to as the "third wave" of psychological interventions after the first wave behavioral and the second wave cognitive interventions. Research relating to MBIs has increased exponentially in the past decade. Key, fully developed, MBIs in the literature include mindfulness-based stress reduction (MBSR), mindfulness-based cognitive therapy (MBCT) and acceptance and commitment therapy (ACT). These interventions are increasingly used with individuals suffering from depression or anxiety and have gained positive findings. Hofmann and colleagues conducted an effect size analysis on 39 studies of MBI for anxiety and mood symptoms in clinical samples. They found a moderately strong uncontrolled pre-post effect size of MBIs on reducing anxiety symptoms and depressive symptoms among individuals with disorders not limited to anxiety disorders or major depression. The authors postulated that MBIs may not be diagnosis-specific. Rather it is effective in reducing stress in general and hence improves symptoms of anxiety and depression across a relatively wide range of conditions.
Since MBIs are efficacious in reducing mood and anxiety symptoms across various disorders, it has potential intervention value for early psychosis as well. In a recent meta-review, Khoury and colleagues concluded that MBIs have moderate therapeutic effects for psychosis. At the same time, there are arguments against mindfulness practices on active psychotic patients, and in people at risk of developing psychosis. In response, Chadwick et al. demonstrated in a feasibility study the safe use of a mindfulness intervention on nine active psychotic patients. Given the small sample size, further careful research, especially randomized controlled trials (RCTs), is needed to support its usage .
Evidence on mindfulness-based interventions in treatment of mood and anxiety symptoms is encouraging. Yet, only a small number of RCTs have been conducted on patients with early psychosis to date. Further, with the limited resources available to the health system in Hong Kong, we aimed to create a simple MBI specific for early psychosis patients, with a user-friendly protocol that can be operated by health practitioners after sufficient yet time-efficient training. Therefore, the current RCT protocol in assessing the efficacy of a brief MBI on patients with early psychosis is of value.
The primary research question is whether positive changes on depressive and anxiety symptoms can be obtained through a 7-week MBI program designed for early psychotic patients. Specifically, we hypothesized that the anxiety level and depressive mood can be significantly reduced by our MBI. The second question we sought to answer is whether this change can be maintained, as reflected in a 3-month follow up. Our secondary hypotheses are that since depression and anxiety are lowered, those receiving the MBI will perceive having better quality of life and overall functioning as a result
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mindfulness
Subjects are scheduled to receive a 7-week group mindfulness-based intervention (MBI) program.
Mindfulness
Mindfulness is the awareness that emerges from paying attention to the present moment without judgment. In this study, subject in this arm will receive 7 weeks of MBI with a focus on tackling anxiety, depressed mood, and attention deficits among early psychosis participants. The elements of 7-week program included mindful-breathing, indoor and outdoor mindful-walking, mindful-eating, mindul-drawing, tree-of-life exercise and closing celebration.
Psychoeducation
Subjects will receive 7 weeks of group-based psychoeducation as an active comparison group parallel to the mindfulness group.
Psychoeducation
Participants in the psychoeducation group will receive seven weeks of psychoeducation sessions which include basic knowledge related to 1) General mental health, 2) Knowledge of psychosis, 3) Treatment and community resources, 4) Recovery and relapse prevention, 5) Healthy lifestyle, 6) Social skills training, and finally a closing celebration at week 7.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mindfulness
Mindfulness is the awareness that emerges from paying attention to the present moment without judgment. In this study, subject in this arm will receive 7 weeks of MBI with a focus on tackling anxiety, depressed mood, and attention deficits among early psychosis participants. The elements of 7-week program included mindful-breathing, indoor and outdoor mindful-walking, mindful-eating, mindul-drawing, tree-of-life exercise and closing celebration.
Psychoeducation
Participants in the psychoeducation group will receive seven weeks of psychoeducation sessions which include basic knowledge related to 1) General mental health, 2) Knowledge of psychosis, 3) Treatment and community resources, 4) Recovery and relapse prevention, 5) Healthy lifestyle, 6) Social skills training, and finally a closing celebration at week 7.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosis of Schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, psychotic disorder not otherwise specified, or manic episodes with psychotic features according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) and less than 5 years' duration since onset of psychosis.
* present with mild depressive or anxiety symptoms (PANSS items G2 or G6 scores higher than or equal to 3; any item on CDSS scores more than or equal to 1).
* They must have an ability to consent, stable positive symptoms (PANSS symptomatic items: P1-P7 scores less than or equal to 3) and good medication compliance (assessed by clinical interview, informant interview, and pill-counting).
Exclusion Criteria
* Known history of intellectual disability,
* Diagnosed with drug-induced psychosis,
* Practice of mindfulness (in forms of yoga, Tai Chi, etc.) more than twice a week during the previous three months,
* Previous or current substance abuse,
* High risk features associated with acute psychotic episodes, and
* Questionable adherence to medication treatment and follow-up.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eric Y H Chen
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
JingXia Lin, PhD
Role: PRINCIPAL_INVESTIGATOR
The University of Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Hong Kong
Hong Kong, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MIND2014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.